A single-center dose-comparison study of botulinum neurotoxin type A in females with upper facial rhytids: Assessing patients' perception of treatment outcomes

Journal of Drugs in Dermatology

Volumn 8, Issue 10, 2009, Pages 924-929

  Carruthers, Alastair ^a   Carruthers, Jean ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; ARTICLE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; FACIES; FEMALE; HUMAN; PROSPECTIVE STUDY; QUESTIONNAIRE; RHYTIDOPLASTY; TREATMENT OUTCOME; WRINKLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUTANEOUS PARAMETERS; DOSE RESPONSE; FACE; MIDDLE AGED; PATIENT SATISFACTION; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; TIME;

ADULT; BOTULINUM TOXIN TYPE A; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FACE; FEMALE; HUMANS; MIDDLE AGED; NEUROMUSCULAR AGENTS; PATIENT SATISFACTION; PILOT PROJECTS; PROSPECTIVE STUDIES; SKIN AGING; TIME FACTORS;

EID: 70350736238     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. American Society of Plastic Surgeons. 2000/2006/2007 National Plastic Surgery Statistics Cosmetic and Reconstructive Procedure Trends. Available at: www.plasticsurgery.org/media/statistics/loader.cfm?url=/commonspot/security/ getfile.cfm&PageID=29287. Accessed May 22, 2008.
2. Carruthers A, Carruthers J, Lowe NJ, et al, for the BOTOX® Glabellar Lines I & II Study Groups. One-year, randomised, multicenter, two-period study of the safety and efficacy of repeated treatments with botulinum toxin type A in patients with glabellar lines. J Clin Res. 2004;7:1-20. (Pubitemid 38843595)
3. Carruthers A, Carruthers J, Cohen J. A prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in female subjects with horizontal forehead rhytides. Dermatol Surg. 2003;29(5):461-467. (Pubitemid 36583142)
4. Carruthers A, Carruthers J. Long-term safety review of subjects treated with botulinum toxin type A for cosmetic use. Poster presented at: American Academy of Dermatology's 62nd Annual Meeting; July 28-August 1, 2004; New York, NY.
5. Carruthers J, Fagien S, Matarasso SL; the Botox Consensus Group. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg. 2004;114(6 Suppl):1S-22S.
6. Rohrich RJ, Janis JE, Fagien S, Stuzin JM. The cosmetic use of botulinum toxin. Plast Reconstr Surg. 2003;112(5 Suppl):177S-188S.
7. Fagien S. Botulinum toxin type A for facial aesthetic enhancement: Role in facial shaping. Plast Reconstr Surg. 2003;112(5 Suppl):6S-18S.
8. Blitzer A, Binder WJ, Aviv JE, et al. The management of hyperfunctional facial lines with botulinum toxin: A collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg. 1997;123(4):389-392. (Pubitemid 27180937)
9. Bulstrode NW, Grobbelaar AO. Long-term prospective follow-up of botulinum toxin treatment for facial rhytides. Aesthetic Plast Surg. 2002;26(5):356-359. (Pubitemid 36919380)
10. Kane MA. Nonsurgical treatment of platysmal bands with injection of botulinum toxin A. Plast Reconstr Surg. 1999;103(2):656-663.
11. Keen M, Blitzer A, Aviv J, et al. Botulinum toxin A for hyperkinetic facial lines: Results of a double-blind, placebo-controlled study. Plast Reconstr Surg. 1994;94(1):94-99. (Pubitemid 24243399)
12. Lowe NJ, Lask G, Yamauchi P, Moore D. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. J Am Acad Dermatol. 2002;47(6):834-840. (Pubitemid 35403040)
13. Matarasso A, Matarasso SL. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg. 2003;112(5 Suppl):127S-140S.
14. Carruthers JA, Lowe NJ, Menter MA, et al, for the BOTOX Glabellar Lines I Study Group. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol. 2002;46(6):840-849.
15. Carruthers JD, Lowe NJ, Menter MA, et al, for the Botox Glabellar Lines II Study Group. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg. 2003;112(4):1089-1098. (Pubitemid 38251807)
16. Mac Pherson S. Self-esteem and cosmetic enhancement. Plast Surg Nurs. 2005;25(1):5-20.
17. Heckmann M, Teichmann B, Schroder U, et al. Pharmacologic denervation of frown muscles enhances baseline expression of happiness and decreases baseline expression of anger, sadness, and fear. J Am Acad Dermatol. 2003;49(2):213-216. (Pubitemid 36951266)
18. Charles Finn J, Cox SE, Earl ML. Social implications of hyperfunctional facial lines. Dermatol Surg. 2003;29(5):450-455. (Pubitemid 36583140)
19. Sommer B, Zschocke I, Bergfeld D, et al. Satisfaction of patients after treatment with botulinum toxin for dynamic facial lines. Dermatol Surg. 2003;29(5):456-460. (Pubitemid 36583141)
20. Cox SE, Finn JC, Stetler L, et al. Development of the Facial Lines Treatment Satisfaction Questionnaire and initial results for botulinum toxin type A-treated patients. Dermatol Surg. 2003;29(5):444-449. (Pubitemid 36583139)
21. Carruthers A and Carruthers J. A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: Safety and efficacy. J Am Acad Dermatol. 2009;60(6):972-979.
22. Kowalski J, Kozma C, Reese PR, et al. Initial development of a patient-completed questionnaire to assess outcomes of aesthetic treatment for hyperfunctional facial lines of the upper face. Poster presented at: American Academy of Dermatology Academy's 2005 Annual Meeting; July 20-24, 2005; Chicago, Ill.
23. Likert RA. A technique for the development of attitude scales. Ed Psychosocial Measure. 1952;12:313-315.
24. Carruthers A, Carruthers J, Said S. Double-blind, randomized, parallel group, dose-ranging study of botulinum toxin type A (BOTOX®, Allergan, Inc.) in the treatment of glabellar lines. Poster presented at: European Academy of Dermatology and Venereology; October 10, 2001; Munich, Germany.
25. Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg. 2005;31(10):1297-1303. (Pubitemid 41587037)
26. Carruthers A, Carruthers JA. Botulinum toxin in the treatment of glabellar frown lines and other facial wrinkles. In: Jankovic J, Hallett M, eds. Therapy with botulinum toxin. New York, NY: Marcel Dekker, Inc.; 1994:577-595.